EGFR and cancer: Anti-inflammatory agents also act as anticancer agents by inhibiting various inflammatory mediators like TNF-α, IL2 IL12, transforming growth factor beta (TGF-β), etc. Scientists have reported that COX2 and EGFR signaling is quite common to both cancer and inflammation, so COX2 inhibitors and the combination of both COX2 and EGFR inhibitors are potential anticancer agents at lower doses.